[1] Forest SK,Hod EA.Management of the platelet refractory patient[J]. Oncol Clin N Am, 2016,30(3):665-677.
[2] Salama OS, Aladl DA, El Ghannam DM, et al.Evaluation of platelet cross-matching in the management of patients refractory to platelet transfusions[J]. Blood Transfus, 2014, 12(2):187-194.
[3] Jia Y,Li W,Liu N,et al.Prevalence of platelet-specific antibodies and efficacy of crossmatch-compatible platelet transfusions in refractory patients[J]. Transfusion Med, 2014,24(6):406-410.
[4] 吴强驹,刘孟黎,齐珺,等. 11755名中国北方汉族造血干细胞供者HLA-A、B、DRB1基因和单倍型研究[J]. 中国实验血液学杂志,2007,15(2):357-363.
[5] 李园,曾惠,吴海兵,等. 患者HPA 1-6,9,15基因多态性对血小板输注无效的临床意义[J]. 中国生化药物杂志,2016,36(4):173-175.
[6] Rebulla P.Formulae for the definition of refractoriness to platelet transfusion[J]. Transfus Med, 1993,3(1):91-92.
[7] Juskewitch J E,Norgan AP,de Goey S R,et al. How do I…manage the platelet transfusion-refractory patient?[J]. Transfusion, 2017,57(12):2828-2835.
[8] Stanworth SJ,Navarrete C,Estcourt L,et al.Platelet refractoriness - practical approaches and ongoing dilemmas in patient management[J]. Br J Haematol, 2015,171(3):297-305.
[9] Pavenski K,Freedman J,Semple J W.HLA alloimmunization against platelet transfusions:pathophysiology,significance,prevention and management[J]. Tissue Antigens, 2012,79(4):237-245.
[10] Hod E,Schwartz J.Platelet transfusion refractoriness[J]. Br J Haematol, 2008,142(3):348-360.
[11] 宋永红,马春红,吕红娟,等. 中国北方汉族人群HLA基因多态性研究[J]. 山东大学学报(医学版),2007,45(6):546-553.
[12] 周丹,张印则,庄乃保,等. 2458名中国汉族人类HPA-1~6、15基因多态性的研究[J].中国输血杂志,2012,25(4):300-303.
[13] 尹作梅,耿贵华,陈晓建. 临沂地区血小板供者HLA-A、B和HPA1-17分型库的建立[J]. 山东医学高等专科学校学报,2017,39(2):99-103.
[14] 冯云飞,宿军,杨春晴,等. 潍坊地区血小板捐献汉族人群HLA-A、B和HPA1-17系统基因多态性研究[J]. 中国输血杂志,2015,28(1):59-62.
[15] Slichter SJ.Evidence-based platelet transfusion guidelines[J]. Hematology Am Soc Hematol Educ Program, 2007:172-178.
[16] Kopko PM,Warner P,Kresie L,et al.Methods for the selection of platelet products for alloimmune-refractory patients[J]. Transfusion, 2015,55(2):235-244.
[17] Cid J,Magnano L,Acosta M,et al.Rituximab,plasma exchange and intravenous immunoglobulins as a new treatment strategy for severe HLA alloimmune platelet refractoriness[J]. Platelets, 2015,26(2):190-194.
[18] Burner J D,Goldfinger D.Potential use of IgG endopeptidase in the management of platelet refractoriness due to HLA alloimmunization[J]. Transfus Apher Sci, 2018,57(3):409-410. |
